OCX Oncocyte

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.

The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: .

An archived replay will be available after the call concludes on iMDX’s investor relations website at .

10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Separately, on August 12th, Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 10th Annual Needham Virtual MedTech & Diagnostics Conference, taking place from August 11-12, 2025.

Investors wishing to book one-on-one meetings with management are encouraged to reach out to their Needham sales representative.

Event: 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Dates: August 12, 2025

Location: Virtual

About Insight Molecular Diagnostics Inc. 

Insight Molecular Diagnostics Inc., or iMDx, formerly Oncocyte Corp. (OCX), is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes.

iMDx™, GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, and VitaGraft™ are trademarks of Insight Molecular Diagnostics Inc. 

Insight Molecular Diagnostics (Nasdaq: IMDX) moved its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025. The company’s new NASDAQ symbol became effective June 18. Investors may visit / for more information.

Investor Contact: 

Doug Farrell 

LifeSci Advisors LLC 



EN
04/08/2025

Underlying

OCXOncocyte

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oncocyte

 PRESS RELEASE
Free
OCX ONCOCYTE

Insight Molecular Diagnostics Announces Positive Strategic Update and ...

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database 5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partnersNew hospital-based data seeks to further differentiate pending kitted assay that measures biomarker for transplanted organ rejection (dd-cfDNA)Novel registry expected to collect approximately 50,000 samples over three years for organ rejection assay combining both percent and total donor derived cell-free DNA into one scoreRegistry expected to assess utility of “the Berlin protocol” of accelerated...

September 8, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcome...

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants iMDx’s ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it is actively enrolling patients in its clinical trial to assess GraftAssureDx and that last week, it enrolled the first patient. In addition, now names 10 leading transpl...

September 8, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

iMDx to Participate in NYC Investment Conferences September 8 - 11

iMDx to Participate in NYC Investment Conferences September 8 - 11 NASHVILLE, Tenn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced participation in investor conferences hosted by both H.C. Wainwright and Lake Street Capital Markets. Information for each can be found below: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8 – 9, 2025Location: In-person at the Lotte New York Palace Hotel and virtual Format: Company presentation on Monday, September 8 at 5:00 pm ET, and one-on-one meetingsLink t...

August 26, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping second generation kits in June NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its second quarter results: Fellow shareholders, We are closer than we have ever been to deli...

August 11, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Att...

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the followin...

August 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch